tiprankstipranks
Trending News
More News >

Cingulate announces results from high-dose fed/fast study of CTx-1301

Cingulate (CING) announced positive top-line results from the CTx-1301-013 study, an FDA required study, assessing the effect of food on absorption of the highest dose of its lead candidate CTx-1301. CTx-1301 is a novel, investigational, trimodal, extended-release tablet formulation of dexmethylphenidate, a compound approved by the U.S. Food and Drug Administration for the treatment of Attention Deficit/Hyperactivity Disorder. The trial demonstrated that 50mg CTx-1301 can be taken with or without food. Multiple pharmacokinetic measurements were taken, and adverse events were consistent with previous findings and indicate a favorable tolerability profile.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1